Lead Product(s) : CS02,Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The topline results of a phase 2 clinical trial of CS02 showed significantly decreases of glycated hemoglobin (HbA1c) in treated patients as compared to placebo group by 0.45%.
Product Name : CS02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 07, 2020
Lead Product(s) : CS02,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable